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Background: Anorexia Nervosa (AN) has a devastating impact on the psychological and physical well being of
affected individuals. There is an extensive body of literature on interventions in AN, however more studies are
needed to establish which form of pharmacotherapy is effective. The few meta-analyses that have been done are
based on one type of medication only. This article is the first to present data on three different, most commonly
used, forms of pharmacotherapy. The primary objective of this meta-analysis was to create an overview and to
determine the efficacy of three forms of pharmacotherapy (antidepressants, antipsychotics, hormonal therapy)
compared to treatment with placebo in patients with AN.
Method: A systematic literature search was performed to identify all randomized controlled intervention trials
investigating the effectiveness of pharmacotherapy for AN within the following databases: PubMed, PsycINFO,
Embase and Cochrane Library. In addition, 32 relevant reviews and meta-analyses were screened for additional
intervention studies. A meta-analysis was performed on a total of 18 included studies (N = 869). Efficacy was
measured in terms of weight gain or weight restoration.
Results: The pooled effect sizes indicating the difference between antidepressants and placebo, and between
antipsychotics and placebo on weight were not significant. Because of the small sample size no meta regression
and subgroup analyses could be conducted. The pooled effect size indicating the difference between hormonal
therapy and the placebo condition on weight (all weight measures) at post-treatment was 0.42 (95% CI: 0.11 ~ 0.73),
which was significant. For hormonal therapy heterogeneity was high (I2 = 64.70). No evidence for publication bias
was found. Meta-regression analyses of the weeks of medication treatment (slope = −0.008) yielded a significant
effect (p = 0.04).
Conclusions: In this study we found that hormonal therapy has a significantly larger effect on weight compared to
placebo in the treatment of AN. However for these analyses heterogeneity was high, which means that these
results have to be regarded with caution. We found that anti-depressants and antipsychotics had no significant
effect on weight compared to placebo in the treatment of AN, although the power to detect significant effects was
too low.
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Anorexia nervosa
Anorexia Nervosa (AN) has a devastating impact on the
psychological and physical wellbeing of affected individ-
uals. The disorder is characterized by restricting intake
of calories and energy which will lead to a low body
weight, extreme fear of gaining weight and being pre-
occupied with behavior that will avoid gaining weight,
and is usually accompanied by a significant disturbance
in the perception of the shape and or size of a person’s
body. In addition, body shape and weight have an undue
influence on the affected persons self-esteem and self-
evaluation [1].
At least 90% of individuals with AN are female. The
prevalence is 0,5% - 1,0%. The course and outcome of
AN are highly variable. AN has a high comorbidity with
depressive symptoms, anxiety and obsessive compulsive
symptoms. For a great part the etiology remains to be
discovered. However, it is clear that a combination of
multiple factors, genetic, neurobiological as well as psy-
chosocial, lead to the development of this disease [2].
Treatment goals in AN include restoration of normal
body weight, treat physical complications, a normal and
healthy eating pattern, improvement of body image and
self-esteem. Equally important is the improvement of
other co morbid psychological symptoms. Because AN is
associated with other psychopathology the treatment is
often long and may involve several stages and interven-
tion types [2].
Treatment
Pharmacotherapy is often used in the treatment of AN.
The fact that pharmacological interventions are estab-
lished forms of treatment of several disorders that overlap
with AN, has led many to conclude that pharmacotherapy
may be useful in symptom reduction in AN [3]. According
to Claudino et al. the rationale for pharmacological treat-
ment of AN is based on neurobiological research into the
control of appetite and food intake and on biological
models of AN, on clinical observations and uncontrolled
studies [4] The focus of pharmacological interventions in
AN depends on the phase of illness. In the acute phase
drugs are given to increase body weight and reduce AN
symptoms (such as recurring thoughts about weight, cal-
oric intake, depression, anxiety and obsessive/compulsive
symptoms). In the second phase pharmacotherapy is
expected to improve underlying psychopathology and
prevent relapse [4,5].
Various types of medication have been studied in the
treatment of AN; antidepressants, antipsychotics, nutri-
tional supplementation and hormonal medication [3,5-7].
Agras and Robinson conclude in their review that there
are no evidence-based psycho-pharmacological treatments
available for either adolescent or adult patients with AN[8]. Two recent meta-analyses have reported on the effect-
ivity of antipsychotics on anorexia nervosa [9,10]. Two
other meta-analyses have been published on the efficacy
of antidepressants and estrogens preparations [4,11]. In
the described meta analyses different outcome measures
were used, for example not only weight, but also bone
health [11]. The overlapping conclusion of these articles is
that more research needs to been done and they recom-
mend the use of similar outcome measures. In this article
we have set a step in that direction. This is the first study
to present meta analyses on three different, most com-
monly used, forms of pharmacotherapy (antidepressants,
antipsychotics, hormonal therapy) and report on the
primary outcome measure for anorexia nervosa; weight.
Lack of evidence
Considering the abovementioned findings, the results of
pharmacotherapy compared to placebo treatment are
scarce. Despite a considerable number of trials per-
formed to elucidate the efficacy of three different forms
of pharmacotherapy on AN, it remains unclear how far
the results can be attributed to placebo effects. This can
be explained by a number of factors; many patients with
AN are difficult to engage in medical treatment and are
unwilling to participate in randomized controlled trials,
and many of these patients are so ill that they require a
multiplicity of interventions [5]. As Powers & Santana
state surprisingly few studies have been undertaken for
AN and more over few studies have actually evaluated
medications know to cause weight gain [12].
Although there are several studies published on AN as a
symptom of other diseases, for example cancer, we chose
to focus on AN as an eating disorder and on randomized
controlled trials with a placebo condition. There are
various systematic reviews exploring pharmacotherapy
for AN but as far as we know only four meta-analyses
have been published on the subject; one meta-analysis
by Claudino et al. [4] that examines the effectivity of anti-
depressants for AN, one that reports on the effects of
estrogen preparations [11] and two on the efficacy on
antipsychotics [9,10]. The present study adds to the
available body of evidence by providing an overview of
the three most commonly used medicament treatments
for AN: antidepressants, antipsychotics and hormonal
medication. The meta-analysis of Sim et al. [11] doesn’t
report on weight as a primary outcome measure, but on
bone density loss. They also included cohort studies
with “no medication” control groups instead of place-
bos. Thus, the present meta-analysis is the first one to
report on the effects of hormonal medication on weight
restoration. Furthermore, this meta-analysis contains an up
to date search; the meta-analyses on antidepressants and
estrogen preparations [4,11] performed their searches until
April 2005 and march 2008 respectively. We chose to focus
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previous meta-analyses have also included studies com-
paring pharmacotherapy with treatment-as-usual [9]
and studies comparing pharmacotherapy with pharma-
cotherapy [4,10]. Finally, subgroup analyses were performed
where possible; only two previous meta-analyses have per-
formed subgroup analyses [9,10].
Method
Search strategy
This meta-analysis is part of broader meta-analysis project
on eating disorders. An extensive electronic database
search for open and randomized controlled trial (RCTs)
was conducted within the following databases: PubMed,
PsycINFO, Embase and Cochrane Library. The search
terms (both text words and MeSH terms) included a
wide range of combined terms indicative of eating dis-
orders (e.g. anorexia nervosa, bulimia nervosa, binge eating
disorder, eating disturbance) and therapy (e.g. psychother-
apy, nutrition therapy, counselling). The Additional file 1
“PubMed search string” contains an example of the search
terms used. The complete search terms and filters used are
available on request from the corresponding author. The
screening process consisted of a number of steps. During
all screening phases, the references were rated by three in-
dependent researchers (JdV, GK, LH). Disagreements were
discussed and resolved in consensus and in cases of unre-
solved disagreement a senior reviewer (JD) was consulted.
Studies were then either included or excluded from further
analysis. The first step consisted of the application of the
inclusion criteria to the 9722 abstracts and titles. Studies
were selected if they (a) reported an author/ had an
abstract, (b) were about treatment of eating disorders,
(c) were written in English or Dutch. In the second phase
the database was split into three eating disorder groups
(Anorexia Nervosa, Bulimia Nervosa and Binge Eating
Disorder). In the third phase we screened 32 earlier re-
views and meta-analyses concerning treatment of eating
disorders for additional relevant studies.
Selection of studies
The next step was to proceed with the anorexia nervosa
studies. For this meta/analysis we focus on randomized
controlled trials. A total of 139 potential anorexia RCTs
remained for a subsequent full-text screening. The data-
base was split into two forms of treatment, pharmaco-
therapy and psychotherapy. In this meta/analysis, we
included studies if they were a (a) randomized controlled
trial, and (b) comparing pharmacotherapy with an pla-
cebo controlled condition and reported on (c) patients
with Anorexia Nervosa with an age minimum of 12 years.
Outcome had to be measured in (d) terms of weight
gain. Studies in the acute and maintenance phase of
treatment were both included.Meta-analysis
We conducted meta-analyses on a) antidepressants,
b) antipsychotics and c) hormonal medication. Those were
the most commonly used pharmacological treatments. For
all three we conducted a separate meta-analysis on weight,
the primary measure, comparing pharmacotherapy versus
placebo.
Primary outcome measures
Most randomized controlled trials report some kind of
weight measure as primary outcome measures. Only
published data were used. The selection of primary out-
come measures for this meta-analyses includes a range
of weight related variables:
Efficacy at the end of treatment, measured in terms of
weight gain or weight restoration as follows:
(a) post weight in kg: the kg of the experimental and
control group at the end of treatment.
(b) post weight in BMI. This is an index for weight in
relationship with height, as reported at the end of
treatment for both experimental and control group.
(c) post weight in IBW. Weight measured in
percentage of Ideal Body Weight.
(d) weight gain in kg and g. The difference in weight
from pre-treatment to post treatment, as reported
at the end of treatment.
(e) IBW gain. The difference in IBW from pre-treatment
to post treatment, as reported at the end of treatment.
(f ) post lean body mass. The fat free mass of the
experimental and control group at the end of
treatment.
(g) post % fat mass. The absolute amount of body fat of
the experimental and control group at the end of
treatment.
Effect sizes (Cohen’s d) were computed for each of the
primary studies. The post- to post-pharmacotherapy
effect sizes were calculated by subtracting the average
post-treatment score of the pharmacotherapy condition
from the average post-treatment score of the placebo
condition and dividing the result by the pooled standard
deviations of both conditions Effect sizes of 0 – 0.32 are
considered to be small, whereas effect sizes of 0.33 – 0.55
are moderate, and effect sizes of 0.56 – 1.2 are large [13].
To calculate the pooled mean effect size, we used the
statistical (computer) program Comprehensive Meta
Analysis (version 2.2.021; Biostat, Englewood, NJ, USA).
Only measures explicitly describing weight at post treat-
ment were used. When means and standard deviations
were not presented, we used other statistics (e.g. t-value,
p-value) to compute the effect size (n = 4). When neither
the means and standard deviations nor a statistical test
between the relevant scores was presented, the study
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meta-analysis.
As an indicator of homogeneity, we calculated Q-
statistics. A significant Q-value rejects the null hypoth-
esis of homogeneity. We also calculated the I2 statistic,
which is an indicator of heterogeneity in percentages. A
low value of 0% indicates that there is no observed hetero-
geneity, higher percentages indicate increasing amounts of
heterogeneity, of which the highest is a value of 75% which
indicates a high amount of heterogeneity (31).
Publication bias was tested according to Duval and
Tweedie's trim and fill procedure [14] using Compre-
hensive Meta-analysis. We ran the publication bias
analyses on all primary outcome measures.
Subgroup analyses
Subgroup analyses were performed using the procedures
implemented in Comprehensive Meta-analysis (version
2.2.021; Biostat, Englewood, NJ, USA). In this subgroup-
analysis, studies were divided into two or more sub-
groups. For each subgroup the pooled mean effect size was
calculated, and a test was conducted to examine whether
the subgroups' effect sizes differ significantly from one an-
other. We used the mixed effect model of subgroup-
analyses, which pools studies within subgroups with the
random effects model, but tests for significant differences
between subgroups with the fixed effects model.
We conducted subgroup analyses for the following
characteristics:
– Mono treatment (only pharmacotherapy or not)
– Setting: inpatient or outpatient or other (not
reported or a combination of in-and outpatient)
The risk of bias quality assessments were based on the
domains described by the Cochrane Collaboration [15].
The domains were evaluated for each study by two inde-
pendent researchers. A code was given for each domain:
yes (=the study reports correctly on this domain and
there is no risk of bias), no (=the study reports on this
domain but according to the description the domain
could be biased) and unclear (=the study does not pro-
vide sufficient information to make an assessment).
Disagreements were discussed and resolved in consensus
and in cases of unresolved disagreement a senior re-
viewer (JD) was consulted. The domains that assessed
the risk of bias are the following:
– Sequence generation: describes whether there was a
random component in sequence generation
– Allocation concealment. describes whether
assignment could be foreseen
– Blinding. Were participants and/or personal blind
for the treatment condition– Incomplete data. Did the study report on missing
outcome data
– Selective outcome. Were all expected outcomes
reported
– Risk of bias. Assesses total risk of bias
Meta regression analyses were performed in order to
assess whether pre-treatment mean weight (kg and
BMI), mean age, duration of illness (in months) and n
weeks predicted the effect sizes. A significant positive or
negative slope suggests that the variable is associated
with the outcome.
Power calculation
Because we expected only a limited number of studies,
we conducted a power calculation to examine how many
studies would have to be included in order to have suffi-
cient statistical power to identify relevant effects. We
conducted a power calculation according to the proce-
dures described by Borenstein and colleagues [16]. We
hoped to find a sufficient number of studies to be able
to identify a small effect size of 0.3. These calculations
indicated that we would need to include at least 20 stud-
ies with a mean sample size of 30 (15 participants per
condition), to be able to detect an effect size of d = 0.30
(conservatively assuming a medium level of between-
study variance, τ2, a statistical power of 0.80, and a sig-
nificance level, alpha, of 0.05). Alternatively, we would
need 15 studies with 40 participants each to detect an
effect size of d = 0.30, or 14 studies with 50 participants.
Results
Inclusion of studies
The search yielded 12.997 results: PubMed (3675), Psy-
cINFO (3660), Embase.com (5382) and Cochrane Library
(280). The latest search update was performed in October
2012. After the duplicates were removed, 9722 titles and
abstracts remained. A flow-chart showing the progress of
the study selection is provided in Figure 1. After the last
screening of full-text articles the search resulted in a total
of 18 studies [17-34], which compared antidepressants,
antipsychotics or hormones with placebo (Table 1 shows
the treatment conditions for each study).
Study characteristics
All 18 studies were randomized controlled trials, report-
ing on a total of 869 subjects. The control conditions in-
cluded 438 subjects and the experimental conditions of
431 subjects. Table 1 presents the study characteristics
of these studies.
The majority of the studies (N = 12) included adult pa-
tients, two reported on adolescents and three reported
on both adults-adolescents. The number of patients in
experimental conditions ranged from 7 to 55 per study.
Figure 1 Flowchart of the search process.
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populations. In the remaining four studies a combin-
ation of clinica l and community recruitment was used.
The larger part of the studies included patients with re-
stricted AN and the binging/purging variant (N = 16),
one study reported on the restricting type only and for
one study it was unknown. Mean pre-treatment weight
score ranged from 14 to 18.1 (BMI). This indicates that
patients were severely underweight. A normal, healthy
BMI ranges from 20 to 25. Six studies reported oninpatients, ten over outpatients, one of patients in a day
care program and one unknown. Only two studies had
male patients.
The majority of studies reported on hormonal treat-
ments (the comparisons were N = 10), six reported on
antipsychotics and four reported on the use of antide-
pressants. A broad variety of adjunctive treatments were
mentioned, such as individual therapy, group therapy,
family therapy, behaviour therapy, caloric repletion, meal
supervision, behavioural incentives and more.






















7 weeks Clinical Restricting/
Binge-purge
1. AD 73 (IBW) 15 26 Fluoxetine 60 mg Inpatient 1. Individual therapy 1.% IBW 27%








8 weeks Clinical Restricting/
Binge-purge
1. AP 16.7 11 12 (1
male)
27.7 Olanzapine Outpatient 1. BMI 26%





10 weeks Clinical Restricting/
Binge-purge
1. AP 16.39 18 29.7 Olanzapine Day hospital 1. Meal supervision 1. BMI 14%






3 months Clinical Unknown 1. AP 15.5 15 23.7 Olanzapine Outpatient 1. CBT 1. BMI 14%




3 months Clinical Restricting/
Binge-purge
1. AP 15.7 10 23 Olanzapine Outpatient 1. CBT 1. BMI n.m.





18 months Clinical Restricting/
Binge-purge































1. GH 17.4 10 28 Nutropin Outpatient 1. Kg ch. 10%
2. Placebo 17.2 11 29.2 15 mg 2.%IBW ch. 18%
3.% lean ch.
4. Lean ch.


















Table 1 Characteristics of the included studies (Continued)
6.% fat ch.
7. Fat mass ch.





9 months Clinical Restricting/
Binge-purge





17 11 30 or 100 mg 2. BMI 19%
3. Placebo 15.6 11 9%
Grinspoon
2002 [25]
6 days Clinical Restricting/
Binge-purge
1. GH + H 35 kg 16 24.2 Recombinant human
IGF-I + Ovcon
Outpatient 1. Calcium 1.Kg 12%





35.4 kg 15 27.6 0
3. Placebo 32.3 kg 15 26.3 7%
Halmi 1986
[26]
32-45 days Clinical Restricting/
Binge-purge
1. AH 79 (IBW) 23 20.56 Amitryptyline Inpatient 1. Days to
target weight
n.m.
2. AD 77 (IBW) 24 160 mg (max) 2. Average kg
gain/day
3. Placebo 75 (IBW) 25
Hill 2000 [27] 28 days Clinical Restricting/
Binge-purge


































2. Placebo 16 10 2.5 mg 2. Psychotherapy 2.%MBW 20%
5 mg 3. Family therapy







1. AD 40.6 (kg) 8 n.m. Clomipramine Inpatient 1. Individual
psychotherapy
1. Kg 25%
2. Placebo 37.7 (kg) 8 50 mg 2. Caloric repletion 2. Mean kg gain 12%


























1. OM/ H 17.8 20 25.2 Risedronate/
Testosterone
Outpatient 1. Kg 23%
2. OM 17.6 20 25.3 35 mg/ 150 mg 2. Lean
body mass
3. H 17.5 19 27.1







1. H 17.4 55 16.5 Fysiologic estrogen
replacement
Outpatient 1. Behavior therapy 1. Kg 56%









1. H 17.9 61 15.2 Norgestimate/ Ethinyl
Estradiol
Outpatient 1. Kg 34%
2. Placebo 17.6 62 15.1 180-250 mg/ 35 mg 2. BMI 21%
Vandereycken
1984 [33]
2x3 weeks Clinical Restricting/
Binge-purge













1. AD 15.4 49 22.4 Fluoxetine Outpatient 1. CBT 1. BMI 57%
2. Placebo 44 24.2 20 mg to 60 mg 2. Family therapy 57%
3. Medication
monitoring
Note. AD = Antidepressants; AH = Antihistamines; AP = Antipsychotics; ch. = change; CBT = Cognitive Behavioral Therapy; GH = Growth hormone; GI = Gastrointestinal; H = Hormones (other); n.m. = not mentioned;
OM = Osteoporosis medication.
aWeight is BMI unless stated otherwise.
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Although all studies were randomized controlled trials,
only five studies were assessed as having a low risk of
bias based on the Cochrane domains [15]. The rest of
the studies were assessed as having a high risk of bias.
Sixteen trials reported blinding for the assessors and/or
the patients and for two it was unknown. A random
component in the sequence generation was reported in
only nine studies; the rest of the studies used a non- ran-
dom approach (N = 2) or did not report it (N = 7). Allo-
cation concealment was done properly in only seven
studies and with a high risk of bias in eleven studies. We
also evaluated the use of incomplete data focusing on
whether or not intention-to-treat analyses were per-
formed. Incomplete data were adequately imputed in ten
cases. Two studies performed completers- only analyses
and six did not report it. Finally, fourteen studies re-
ported all their outcomes, two studies reported only sig-
nificant outcomes and for two studies it was unclear.
Table 2 presents the quality assessment per study.
Weight was assessed in various ways. We reported on
combined ES. To assure that this did not influence the
results we performed the meta/analyses including for ex-
ample only BMI or kg. This did not have an effect on
the results, we therefore report on all weights. SomeTable 2 Risk of bias assessments
Study Sequence generation Allocation concealment
Attia, 1998 [17] No No
Attia, 2011 [18] Yes Yes
Bissada, 2008 [19] Yes Yes
Brambilla, 2007a [20] Unclear Unclear
Brambilla, 2007b [21] Unclear Unclear
Di Vasta 2012 [22] Yes Yes
Fazeli 2010 [23] Unclear Unclear
Grinspoon 1996a [24] Unclear Unclear
Grinspoon, 1996b [24] Unclear Unclear
Grinspoon, 2002a [25] Yes Unclear
Grinspoon, 2002b [25] Yes Unclear
Halmi 1986 [26] Unclear Unclear
Hill 2000 [27] Yes Unclear
Kafantaris 2011 [28] Yes Yes
Lacey 1980 [29] No Unclear
Miller 2011 [30] Unclear Unclear
Misra 2011 [31] Yes Unclear
Strokosch 2006 [32] Yes Unclear
Vandereycken 1984 [33] Unclear Unclear
Walsh 2006 [34] Yes Yes
Note. yes (=the study reports correctly on this domain and there is no risk of bias);
domain could be biased); unclear (=the study does not provide sufficient informatiostudies had weight measures such as weight gain and
IBW gain [17,23,26,27,29,33]. To ensure that this was a
valid approach we looked at the equivalence of weight
measures of the groups at baseline. Almost all studies
(except Halmi, 1986) mentioned explicitly that there
were no significant differences in weight at time of
randomization.
Pharmacotherapy versus placebo
Before performing the three meta-analyses of the most
commonly used pharmacotherapy, we performed a meta-
analysis comparing all three forms of pharmacotherapy
with placebo. There were 20 studies that reported out-
comes on weight. Figure 2 presents the outcomes of the
meta-analysis.
The pooled effect size at post-treatment was 0.33,
(95% CI: 0.14 ~ 0.52), indicating a significant effect. Het-
erogeneity was medium/ high (I2 = 40.08). There was
one outlier [25]; when removed the effect size decreased
and became 0.25, still remaining significant. When the
outlier was removed, heterogeneity became low (I2 = 0).
There was no evidence of publication bias. Subgroup
analyses yielded no significant differences between sub-
groups. Meta regression analyses for mean age (slope =
0.014), duration of illness (slope = 0.014), mean weeks ofBlinding Incomplete data Selective outcome Total risk of bias
assessment
Yes Yes Yes High
Yes Yes Yes Low
Yes No Yes Unclear
Yes Unclear Yes Unclear
Yes Yes Yes Unclear
Yes Yes Yes Low
Unclear Unclear Yes Unclear
Yes Unclear Unclear High
Yes Unclear Unclear High
Yes Yes Yes Unclear
Yes Yes Yes Unclear
Yes Unclear No Unclear
Yes Unclear Unclear Unclear
Yes Yes Yes Low
Yes Yes Yes Unclear
Yes No No Unclear
Yes Yes Yes Low
Yes No Yes Unclear
Yes Unclear Yes Unclear
Yes Yes Yes Low
no (=the study reports on this domain but according to the description the
n to make an assessment).
Figure 2 Effects of pharmacotherapy vs. placebo on weight.
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ning of treatment (slope = 0.040) yielded no significant as-
sociations (p = 0.36; p = 0.89; p = 0.54; p = 0.50 respectively).
Antidepressants versus placebo
There were 4 studies that reported outcomes on weight
(see Figure 3). The pooled effect size indicating the dif-
ference between antidepressants and the placebo condi-
tion on weight (all weight measures) at post-treatment
was 0.26 (95% CI: −0.03 ~ 0.56), which was not signifi-
cant (Table 3).
The heterogeneity for Antidepressants was low (I2 = 0).
The effect size comparing antidepressants with placebo
at post-treatment was higher when adjusted for publica-
tion bias (d = 0.35; 95% CI: 0.06 ~ 0.64; number ofFigure 3 Effects of antidepressants vs. placebo on weight.trimmed studies = 1, right of mean), indicating a signifi-
cant effect.
Because of the small sample size no meta regression
or subgroup analyses could be conducted.Antipsychotics versus placebo
Figure 4 shows that there were 6 studies that reported
the effects of antipsychotics on weight. The pooled effect
size indicating the difference between antipsychotics and
the placebo condition on weight (all weight measures) at
post-treatment was 0.25 (95% CI: −0.09 ~ 0.60), which
was not significant (Table 3).
The heterogeneity for Antipsychotics was low (I2 = 0.00).
No evidence for publication bias was found. Because of the
Table 3 Meta-analyses of studies examining the effects of pharmacotherapy versus placebo for anorexia nervosa
N d 95% CI Z p Q I2
Pharmacotherapy vs. placebo 20 0.33 0.14 ~ 0.52 3.47 0.00 31.71 40.08
Outlier removed 19 0.25 0.11 ~ 0.39 3.45 0.00 16.28 0.00
Antidepressants vs. placebo 4 0.26 −0.04 ~ 0.56 1.73 0.08 2.11 0.00
Antipsychotics vs. placebo 6 0.25 −0.09 ~ 0.60 1.43 0.15 3.74 0.00
Hormonal treatment vs. placebo
All studies 10 0.42 0.11 ~ 0.73 2.67 0.01 25.50 64.70
Outlier removed 9 0.26 0.04 ~ 0.47 2.37 0.02 10.41 23.15
One effect size per study (highest excluded) 8 0.21 0.02 ~ 0.39 2.19 0.03 7.09 1.26
One effect size per study (lowest excluded) 8 0.45 0.07 ~ 0.83 2.31 0.02 25.39 72.43
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lyses could be done.
Hormonal pharmacotherapy versus placebo
There were 8 studies that reported on weight and 10
comparisons because of multiple conditions in some
studies [24,25]; see Figure 5). Grinspoon et al. [24] ad-
ministered 30 mg and 100 mg of recombinant human
insulin-like growth factor I. In Grinspoon et al. [25] the
therapeutic conditions consisted of recombinant human
IGF-I and oral contraceptive administration. The pooled
effect size indicating the difference between hormonal
therapy and the placebo condition on weight (all weight
measures) at post-treatment was 0.42 (95% CI: 0.11 ~
0.73), which was significant (Table 3).
For hormonal therapy heterogeneity was high (I2 =
64.70). No evidence for publication bias was found.
There was one outlier [25]; when removed the effect size
decreased and became 0.26, still remaining significant.
When the outlier was removed, heterogeneity became a
bit lower (I2 = 23.15). Meta-regression analyses of the
weeks of medication treatment (slope = −0.008) yielded a
significant effect (p = 0.04). Meta regression analyses of
BMI at the beginning of treatment (slope = −0.02326)
and mean age (slope = 0.03932) yielded no significantFigure 4 Effects of antipsychotics vs. placebo on weight.effects (p = 0.83; p = 0.05 respectively). Subgroup ana-
lyses for hormonal therapy did not yield any significant
results.
In this meta-analysis we included two studies in which
two hormonal treatments were compared with the same
control group [24,25], thus resulting in multiple compar-
isons in the same analysis. Because those comparisons
are not independent from each other, this may have re-
sulted in an artificial reduction of heterogeneity and
have influenced the pooled effect size. We therefore per-
formed a sensitivity analysis by including only one effect
size per study. First, we conducted the analysis including
only the comparison with the largest effect size from
that study and then we did the same with the smallest ef-
fect size. As can be seen in Table 3, excluding the highest
effect sizes resulted to a smaller (still significant) effect
size and a large reduction in heterogeneity (I2 = 1.26).Discussion and conclusion
Main findings
To our knowledge this is the first meta analysis focusing
on three forms of pharmacotherapy in the treatment of
AN. By analyzing these data we aimed to provide an over-
view of more detailed information of the effectiveness of
Figure 5 Effects of hormonal medication vs. placebo on weight.
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placebo.
When grouping all medication together, we found that
pharmacotherapy is more effective than placebo. This
grouping allowed an increase in power in order to per-
form subgroup and meta regression analyses. Unfortu-
nately, they did not yield significant results. When
performing meta-analyses for the three most common
medicine apart, we found that hormonal therapy has a
significantly larger effect on weight compared to placebo
in the treatment of AN. This is a moderate effect size
[13]. However for these analyses heterogeneity was high,
which means that these significant results have to be
regarded with caution. The sensitivity analyses support
this conclusion. Meta regression analyses suggest that
less weeks of hormonal treatment are associated with a
better effect (a significant negative slope). It is possible
that anorexia patients benefit on short term when it
comes to (hormonal) medication, but fail to have a bet-
ter recovery on long term. There are indications that for
example alterations in the regulation of the hormone leptin
may play a part in the persistence of anorexia nervosa.
During recovery of anorexia patients, normalization of lep-
tin levels seems to precede normalization of weight; this
may be a contributing factor to the difficulties patients ex-
perience with maintaining normal weights, in this case for
longer treatments [35]. Larger effect sizes for weight do
not necessarily mean normalization of weight. Further-
more, weight goals differ depending on the treatment
phase (acute phase or maintenance phase). In the acute
phase the aim of treatment is mostly weight gain. However,
weight gain alone cannot be considered a successful treat-
ment of AN as other symptoms may continue to exist (e.g.
absence of menstruation, preoccupation with body weight).
Most trials focus on weight restoration; unfortunately this
is only one aspect of the complex pathology of AN.We found that antidepressants had no significant ef-
fect on weight compared to placebo in the treatment of
AN. [4] found that antidepressants did not only fail to
improve weight when compared to placebo, but also eat-
ing related psychopathology. However when we adjusted
for publication bias the effect became higher, and signifi-
cant favouring antidepressants over placebo treatment.
Claudino et al. however only included subjects in the
acute underweight phase, while this meta-analysis had
broader criteria (acute and maintenance phase).
This meta-analysis also suggests that antipsychotics
had no significant effect on weight compared to placebo
in the treatment of AN. This latter is in line with the
findings of Kishi et al. [9] and Lebow [10]. Kishi con-
cludes on basis of their results that “taken together, the
currently available evidence seems to tilt the risk-benefit
balance against antipsychotics in patients with anorexia
nervosa”.
Considering the grave consequences of AN all small
steps that are helpful in treatment should be taken into
consideration. However the results of this study should
be interpreted within the study’s limitations.
Antidepressants and antipsychotics are the most
commonly used medicamental treatments for anorexia
nervosa in the Netherlands. Yet in both cases we failed
to reveal efficacy when compared to placebo. There
has been a lot of research trying to explain the placebo
response, focusing on non/specific factors, expectancy
and conditioning. Some studies have tried to identify
“placebo prone personality types” with no consistent
conclusions. There are some indications that use
others as a healing resource and build positive rela-
tionships tend to benefit more from placebos, a hy-
pothesis that supports continuity of care and effective
interpersonal relationships to produce those placebo
effects [36].
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psychotic trials also raise an ethical dilemma: should
those medications be used to treat anorexia nervosa in
the acute phase? Clinicians should consider whether it is
more beneficial to treat anorexia nervosa patients with
pharmacotherapy in the stabilisation or prevention re-
lapse phase, not aiming only at weight but also second-
ary symptoms as depression (see also the conclusion of
Claudino et al. [4]). The design of the studies included
also raise moral dilemmas. For example, how ethical is it
to withhold treatment from anorexic patients and offer
them a placebo instead? Furthermore, not all studies
reported funding information. This aspect is essential
when medication trials are published.
Limitations and recommendations
Several limitations of our meta analysis caution against
over-interpretation of the results. One methodological
shortcoming is that the quality of the 18 included
studies was not optimal and some of the studies had
very small sample sizes. Six out of eight studies of hor-
monal therapy for example had an unclear or high risk
of bias. Yet those studies yielded positive findings. The
power was an important problem, we could not include
the number of studies that were necessary according to
power calculations, which unfortunately made it impos-
sible to run subgroup analyses for antidepressants and
antipsychotics.
The studies contain relatively small patient samples,
lending the results to a narrow foundation. In addition
there is major variety in treatment and patient groups.
The heterogeneity in the comparison between hormonal
therapy and placebo was large. Furthermore some pa-
tients in the experimental as well as control conditions
received various forms of adjunctive treatment, varying
from very intensive clinical treatment to weekly out-
patient sessions, making it difficult to draw conclusions.
Some studies included adolescents as young as 12 years
old. Changes in weight could be attributed to growth
and not medication, especially in longer RCT’s.
Other methodological shortcomings of the studies in-
volve the outcome measures and reporting of outcomes.
Although we've tried to report on many outcome mea-
sures and subgroups, this on the one hand reduced our
sample sizes considerably, making it very hard to draw
conclusions. On the other hand it lead to a lot of irrele-
vant results. Furthermore, the primary outcome measure
was improvement of weight, as this is considered the
first step in recovering from AN. Most of the trials
therefore reported on weight, but unfortunately did so
in various ways, making aggregation of the results very
difficult, if not impossible. More over a number of
studies only reported significant results, leaving out non
significant but possibly relevant data and information.Because we inserted published data only, this may have
caused a bias in our analyses.
Some evidence of heterogeneity was found between
studies. Two main reasons for this could be that studies
were found to be pursuing similar objectives (improve-
ment in the treatment of AN) but with differences in
goals and in expected actions of the pharmacological
interventions.
Recommendations
Although considerable research had been devoted to AN
evidence considering treatment efficacy is scarce. As
demonstrated in this MA, trials reporting on pharmaco-
therapy compared to placebo had major limitations.
Therefore it is of extreme importance that researchers
would systematically use the same outcome measures.
Furthermore the use of dichotomous data or the use of
categories of levels of improvement in symptoms would
facilitate research in the future. There is an urgent need
for more and better quality studies with a better opera-
tionalization of the terms of improvement for AN. RCT’s
need to focus not only on weight restoration but on a
broader definition of improvement. In these future stud-
ies, researchers must also attend to issues of statistical
power and research design.
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